December 22, 2014 10:53 AM ET

Pharmaceuticals

Company Overview of Blend Therapeutics, Inc.

Executive Profile

Mark Iwicki

Chief Executive Officer, President and Director, Civitas Therapeutics, Inc.
AgeTotal Calculated CompensationThis person is connected to 3 Board Members in 3 different organizations across 4 different industries.

See Board Relationships
47--

Background

Mr. Mark Iwicki has been the Chief Executive Officer and President of Civitas Therapeutics, Inc. since January 29, 2014. Mr. Iwicki has more than 23 years of experience as a pharmaceutical industry leader managing all stages of drug development in multiple therapeutic areas. He has extensive experience managing high-performance teams and is instrumental in the success of a number of drugs, including Prilosec, Diovan, Zelnorm, Lunesta, and Latuda. He served as President ...

Corporate Headquarters

134 Coolidge Avenue
Watertown, Massachusetts 02472

United States

Phone: 617-923-4100
Fax: 617-923-4101

Board Members Memberships

Director
2010-2012
Former President, Chief Operating Officer and Director
2012-Present
Director
2014-Present
Chief Executive Officer, President and Director

Education

MBA
Loyola University Maryland
BS
Ball State University

Other Affiliations

Annual Compensation

There is no Annual Compensation data available.

Stocks Options

There is no Stock Options data available.

Total Compensation

There is no Total Compensation data available.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

COMPETITOR COMPENSATION

There is no Competitor Compensation data available.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Blend Therapeutics, Inc., please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.